Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey

被引:10
|
作者
Kaur, Sukhpal [1 ]
Singh, Ajay [2 ]
Saini, Sushma [1 ]
Rohilla, Latika [1 ]
Kaur, Jasvir [1 ]
Chandi, Anadeep [3 ]
Kaur, Gurpreet [1 ]
Singh, Manjeet [9 ]
Kumar, Pramod [1 ]
Soni, Shiv Lal [10 ]
Kajal, Kamal [2 ]
Naik, Naveen B. [2 ]
Malhotra, Pankaj [4 ]
Verma, Sanjay [5 ]
Gupta, Madhu [6 ]
Devnani, Mahesh [7 ]
Das, Karobi [1 ]
Pandav, S. S. [8 ]
Puri, G. D. [2 ]
机构
[1] Govt Multispecial Hosp, Natl Inst Nursing Educ, Dept Nursing, Chandigarh, India
[2] Govt Multispecial Hosp, Dept Anaesthesia & Intens Care, Chandigarh, India
[3] Govt Multispecial Hosp, Dept Obstet & Gynaecol, Chandigarh, India
[4] Govt Multispecial Hosp, Dept Internal Med, Chandigarh, India
[5] Govt Multispecial Hosp, Dept Paediat, Chandigarh, India
[6] Govt Multispecial Hosp, Dept Community Med, Chandigarh, India
[7] Govt Multispecial Hosp, Hosp Adm, Chandigarh, India
[8] Multispecial Hosp, Postgrad Inst Med Educ & Res, Ophthalmol, Chandigarh, India
[9] Govt Multispecial Hosp, Dept Med, Chandigarh, India
[10] Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Sect 12, Chandigarh 160012, India
关键词
Adverse events; ChAdOx1; nCoV-19; coronavirus disease 2019; healthcare professionals; side effects; vaccination;
D O I
10.4103/ijmr.ijmr_1221_21
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: The safety of the ChAdOx1 nCoV-19 vaccine is a cause of concern for many who have been vaccinated. The people have multiple concerns and fear regarding the adverse events of the vaccine. Thus, this study was undertaken to establish the safety profile of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) among the healthcare professionals. Methods: This was a descriptive cross-sectional survey. After taking clearance from the institutional ethics committee 1500 healthcare professionals, who had their vaccination in the past two weeks were selected. They were provided with an online survey proforma regarding adverse events following immunization (AEFIs) of COVID-19 vaccine developed using google forms with an informed consent form affixed to it. Results: A total of 1036 individuals participated in the study. The mean and median (inter quartile range) age of the participants was 37.7 +/- 11.25 and 35 (29-46) yr, respectively. Of these, 52.1 per cent were female, 29.3 per cent were doctors, 33.4 per cent were nurses and 9.5 per cent were paramedical staff. Forty six per cent participants experienced one or more minor AEFIs such as pain, tenderness, redness, etc. at the injection site. Fatigue (31.75%), generalized feeling of unwell (28.57%), muscle pain (23.16%) and fever (21.71%) were the most commonly reported systemic AEFIs followed by headache (20.07%), dizziness (10.03%) and joint pains (15.25%). Most of them experienced these AEFIs within 24 h of the first dose of administration. About 42 per cent of the participants took oral antipyretics/analgesics for managing the AEFIs. Interpretation & conclusions: ChAdOx1 nCoV-19 Corona Virus Vaccine was found to be associated with mild local and systemic AEFIs that were more common after the first dose as compared to the second dose. There adverse events could be dealt with oral over-the-counter medications, with no requirement of hospitalization.
引用
收藏
页码:123 / 128
页数:6
相关论文
共 50 条
  • [1] Healthcare professionals & adverse events of ChAdOx1 nCoV-19 coronavirus vaccine Response
    Kaur, Sukhpal
    Singh, Ajay
    Saini, Sushma
    Rohilla, Latika
    Kaur, Jasvir
    Chandi, Anadeep
    Kaur, Gurpreet
    Singh, Manjeet
    Kumar, Pramod
    Soni, Shiv Lal
    Kajal, Kamal
    Naik, Naveen B.
    Malhotra, Pankaj
    Verma, Sanjay
    Gupta, Madhu
    Devnani, Mahesh
    Das, Karobi
    Pandav, S. S.
    Puri, G. D.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2022, 155 (5-6) : 591 - 592
  • [2] Herpes zoster triggered by ChAdOx1 nCoV-19 coronavirus vaccine (recombinant)
    George, Neethu Mary
    NATIONAL MEDICAL JOURNAL OF INDIA, 2024, 37 (02): : 89 - 90
  • [3] Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine
    Huh, Kyungmin
    Na, Yewon
    Kim, Young-Eun
    Radnaabaatar, Munkhzul
    Peck, Kyong Ran
    Jung, Jaehun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (27) : 1 - 6
  • [4] Herpes Zoster Following Vaccination with ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant)
    Job, Anupa Mary
    Sudhamani, Bindurani
    Mohan, Manju
    Mohanasundarama, S. N.
    INDIAN JOURNAL OF PUBLIC HEALTH, 2022, 66 (01) : 83 - 85
  • [5] Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal
    Rayamajhi, Sushil
    Rafi, Md. Abdur
    Tripathi, Nishant
    Dongol, Anjana Singh
    Pandey, Minalma
    Rayamajhi, Shreejana
    Bhandari, Subhechchha
    Shrestha, Pranay
    Hasan, M. Tasdik
    Hossain, Md. Golam
    PLOS ONE, 2022, 17 (08):
  • [6] Active Symptom-Based Surveillance of Adverse Events Following Immunization Among Individuals Vaccinated with ChAdOx1 nCoV-19 Coronavirus Vaccine in a Tertiary Hospital of Kerala
    Jose, Maria
    Rajmohan, Priyanka
    Thomas, Joe
    Krishna, Swathi
    Antony, Beena
    Gopinathan, Unnikrishnan U.
    Iyyapan, Elsy M.
    Porinchu, Raphael M.
    Jose, Ponnu
    Raphael, Lucy
    Kuttichira, Praveenlal
    CURRENT DRUG SAFETY, 2022, 17 (04) : 327 - 334
  • [7] Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea
    Jeon, Minji
    Kim, Jehun
    Oh, Chi Eun
    Lee, Jin-Young
    VACCINES, 2021, 9 (10)
  • [8] Emergence of COVID-19 variants among ChAdOx1 nCoV-19 (recombinant) vaccine recipients
    Vaishya, Raju
    Sibal, Anupam
    Singh, Sujeet Kumar
    Malani, Arpita
    Das, Shreya
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2021, 153 (05) : 559 - 561
  • [9] Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021
    Yao Rodion Konu
    Fifonsi Adjidossi Gbeasor-Komlanvi
    Mouhoudine Yerima
    Arnold Junior Sadio
    Martin Kouame Tchankoni
    Wendpouire Ida Carine Zida-Compaore
    Josée Nayo-Apetsianyi
    Kossivi Agbélénko Afanvi
    Sibabe Agoro
    Mounerou Salou
    Dadja Essoya Landoh
    Atany B. Nyansa
    Essohanam Boko
    Moustafa Mijiyawa
    Didier Koumavi Ekouevi
    Archives of Public Health, 79
  • [10] Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021
    Konu, Yao Rodion
    Gbeasor-Komlanvi, Fifonsi Adjidossi
    Yerima, Mouhoudine
    Sadio, Arnold Junior
    Tchankoni, Martin Kouame
    Zida-Compaore, Wendpouire Ida Carine
    Nayo-Apetsianyi, Josee
    Afanvi, Kossivi Agbelenko
    Agoro, Sibabe
    Salou, Mounerou
    Landoh, Dadja Essoya
    Nyansa, Atany B.
    Boko, Essohanam
    Mijiyawa, Moustafa
    Ekouevi, Didier Koumavi
    ARCHIVES OF PUBLIC HEALTH, 2021, 79 (01)